Acute visual loss after initiation of antihypertensive therapy: case report

Norman Mainville, W.E.S. Connolly

Abstract

WE REPORT THE CASE OF A 50-year-old man who reported sudden, painless loss of vision in his left eye after starting antihypertensive therapy. Potential causes of acute painless unilateral visual loss are discussed, as is the initial management of hypertension in asymptomatic patients.

Case

A 50-year-old man came to the emergency department with a 36-hour history of painless decreased vision in his left eye. He had seen his family doctor 3 days earlier to report

dizziness and had been found to have a blood pressure of 195/130 mm Hg. At that time, his doctor had prescribed fosinopril (20 mg/d) and hydrochlorothiazide (25 mg/d). On waking the next morning, the patient had noted loss of vision in his left eye, with no pain. When his vision had not improved a day later, he went to the emergency department.

The patient denied experiencing fever, headache, nausea, vomiting, scalp tenderness or jaw claudication. He had no significant medical history and was not taking any medications other than the 2 prescribed for his hypertension. His family history was negative for cardiac disease, diabetes mellitus and eye problems.

Examination showed the patient to be afebrile with a blood pressure of 161/85 mm Hg. Visual acuity was 20/20 (metric 6/6) in the right eye; with the left eye he could detect only hand movements. An afferent pupillary defect was noted in the left eye. The right eye appeared normal on fundus examination; however, a pale, edematous retina was noted in the left eye, with a characteristic cherry-red spot (Fig. 1). There was no evidence of retinal emboli in either eye. The patient had a normal complete blood cell count and a normal erythrocyte

sedimentation rate (1 mm/h). An ophthalmologist was consulted. Based on the duration of the patient's visual loss, the opinion was that any therapeutic intervention would be unlikely to improve vision.

The patient was re-examined the following morning, at which time his blood pressure was 113/90 mm Hg. An angiogram showed a normal right eye and delayed arterial filling in the left eye consistent with a central retinal artery occlusion (Fig. 2). The Doppler scan showed small plaques in the left and right common carotid arteries, with a 16%–49% stenosis of the left proximal common carotid artery, but there were no significant hemodynamic abnormalities in either the carotid or vertebral circulation.




Fig. 1: Left: Normal appearance of right eye on funduscopic examination. Right: Cherryred spot in left eye with extensive retinal edema and pallor secondary to retinal artery occlusion. The foveal region appears cherry red because the surrounding retina is edematous and appears white, thereby accentuating the normal red foveal reflex coming from the choroidal circulation. Choroidal circulation is usually unaffected in central retinal artery occlusion.




Fig. 2: Fluorescein angiograms, taken several minutes after infusion of contrast medium. Left: The vasculature of normal right eye demonstrated early filling and passage of dye. Right: The left eye showed markedly delayed passage of fluorescein, with filling of its arterial tree beginning several minutes after the infusion.

During follow-up visits with his family doctor, the patient's blood pressure was found to vary between 170/110 and 130/84 mm Hg after the addition of nifedipine. At a follow-up visit 14 months after the initial event, vision in his left eye had improved slightly, such that he was able to count fingers.

Comments

Vascular insufficiency is the most common cause of sudden painless unilateral loss of vision (Table 1).¹⁻³ Retinal ischemia can result from direct occlusion of the central retinal artery by an embolism from the left atrium or carotid arteries.^{4,5} The resulting ischemia may be either transient (amaurosis fugax) or persistent (central retinal artery occlusion). Inflammatory conditions (e.g., giant cell arteritis) are a significant preventable cause of visual loss.⁶ Acute-onset visual loss resulting from systemic hypotension has been reported previously.⁷⁻⁹

Acute-onset visual loss requires urgent ophthalmologic consultation.¹⁰ Treatment needs to be started within 4 hours after onset for any chance of restoring normal vision.¹¹ If treatment is delayed for more than 24 hours, significant improvement in visual acuity is highly unlikely.

Table 1: Nontraumatic causes of sudden, painless, profound visual loss

104411000	
Diagnosis	Clinical findings
Amaurosis fugax	Sudden complete loss of vision lasting less than 2 hours. Retina appears normal
Central retinal artery occlusion	Sudden, profound visual loss; arteriolar narrowing. Early findings (within minutes or hours): vascular stasis, arterial and venous "boxcaring" (breakup of blood flow in a small vessel into clumps of red blood cells, giving the appearance of boxcars moving through the vessel). Late findings (within hours or days): retinal edema and pallor, cherry-red spot
Ischemic optic neuropathy, arteritic (e.g., giant-cell arteritis)	Sudden visual loss, often with a hemifield defect. Optic disk edema and nerve fibre layer (flame-shaped) hemorrhages around optic nerve head. Associated complaints of headache, fever, weight loss, joint or muscle tenderness, scalp tenderness and jaw claudication
Ischemic optic neuropathy, atherosclerotic	Sudden visual loss, often with a hemifield defect. Optic disk edema and nerve fibre layer (flame-shaped) hemorrhages around optic nerve head
Retinal vein occlusion	Subacute onset of visual loss, sometimes severe. Retinal findings: diffuse retinal hemorrhages extending to periphery, venous engorgement, disc swelling, cotton-wool spots
Extensive retinal detachment	Visual acuity may be normal if macula still attached; usually some field defect is present. History of flashing lights, floaters and a curtain being drawn over vision. Retina appears elevated, sometimes folded with indistinct choroidal background

Therapeutic options for central retinal artery occlusion are aimed at either reducing intraocular pressure (through ocular massage, anterior chamber paracentesis or acetazolamide therapy) or attempting to dislodge or reduce the embolus (through localized thrombolysis or ocular massage). In our patient's case, the use of any of these therapies would have had little effect on his clinical outcome, because he had experienced visual loss for 36 hours at the time of presentation.

Chronic hypertension can induce hypertrophy of the tunica muscularis of the arterial wall, causing narrowing of the lumen and an increase in peripheral vascular resistance.¹² As a result of these changes, a rapid drop in systemic blood pressure may compromise cerebral perfusion and lead to ischemia and injury in susceptible tissue, such as the retina.

In patients such as ours, who are less than 60 years old with uncomplicated hypertension, initial treatment should consist of a trial of monotherapy with a thiazide diuretic, β-blocker or angiotensin-converting-enzyme (ACE) inhibitor. Combination therapy should be attempted only if adequate blood pressure control is not achieved with monotherapy. The supplier's product monograph for Monopril (fosinopril) specifically warns of the danger that "patients concomitantly taking ACE inhibitors and diuretics, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction in blood pressure after initiation of therapy." During the initial studies of fosinopril in placebo-controlled heartfailure trials, 0.8% of patients were reported to have discontinued treatment as a result of first-dose hypotension. 14,15

Before experiencing his visual loss, our patient had gone to his family physician because of dizziness, but he was otherwise asymptomatic. He had been prescribed combined therapy with fosinopril, at twice the recommended starting dose, and hydrochlorothiazide. Although his loss of vision may have resulted solely from a thromboembolic event arising from a ruptured atheromatous plaque, this seems unlikely given his age and lack of prior visual or neurological symptoms. Rather, the rapid reduction in his systemic blood pressure was likely the primary cause, and the stenosis of his proximal left common carotid artery contributed secondarily.

In summary, hypertension is a chronic medical condition to which the body responds with vascular remodelling to maintain the requisite tissue perfusion and oxygen delivery for normal physiological functioning. In the absence of manifestations of hypertensive encephalopathy (severe headache, vomiting, visual field disturbances, transient paralyses, convulsions, stupor or coma) or clinical findings suggesting pathological changes resulting from elevated blood pressure (papilledema, retinal hemorrhages and exudates), a conservative approach should be taken toward normalizing blood pressure. Sudden reduction of blood pressure through the administration of multiple antihypertensive medications may result in hypoperfusion and ischemic injury to susceptible tissues.

This article has been peer reviewed.

At the time of writing, Dr. Mainville was a McGill University medical student and was a PhD candidate in the Division of Experimental Medicine, Montreal General Hospital, Montréal, Que. Dr. Connolly is Associate Professor of Ophthalmology, McGill University, and Chief of Ophthalmology, St. Mary's Hospital, Montréal, Que.

Competing Interests: None declared.

Contributors: Both authors contributed to the drafting of the article and its critical revision and approved the version to be published.

References

- Whitmore PV. Sudden painless visual loss: retinal causes. Clin Geriatr Med 1999:15:15-24
- Beatty S, Eong KGA. Acute occlusion of the retinal arteries: current concepts and recent advances in diagnosis and management [review]. J Accid Emerg Med 2000;17:324-9.
- Fraser S, Siriwardena D. Interventions for acute non-arteritic central retinal artery occlusion [review]. Cochrane Database Syst Rev 2002;(1):CD001989.
- Salehian O, Demers C, Patel A. Atrial myxoma presenting as isolated unilateral blindness: a case report and review of the literature. Can J Cardiol 2001; 17:898-900.
- Sharma S. The systemic evaluation of acute retinal artery occlusion. Curr Opin Ophthalmol 1998;9:1-5.

- Schauble B, Wijman CA, Koleini B, Babikian VL. Ophthalmic artery microembolism in giant cell arteritis. *J Neuroophthalmol* 2000;20:273-5.
 Katz DM, Trobe JD, Cornblath WT, Kline LB. Ischemic optic neuropathy
- Katz DM, Trobe JD, Cornblath WT, Kline LB. Ischemic optic neuropathy after lumbar spine surgery. Arch Ophthalmol 1994;112:925-31.
- Minagar A, Schatz NJ, Glaser JS. Liposuction and ischemic optic neuropathy. Case report and review of literature. J Neurol Sci 2000;181:132-6.
- Remigio D, Wertenbaker C. Post-operative bilateral vision loss. Surv Ophthalmol 2000;44:426-32.
- Morgan A, Hemphill RR. Acute visual change. Emerg Med Clin North Am 1998;16:825-43.
- Cullom RD Jr, Chang B, editors. The Wills eye manual: office and emergency room diagnosis and treatment of eye disease. 2nd ed. Philadelphia: Lippincott; 1994.
- Glasser SP. On arterial physiology, pathophysiology of vascular compliance, and cardiovascular disease. *Heart Dis* 2000;2:375-9.
 Feldman RD, Campbell N, Larochelle P, Bolli P, Burgess ED, Carruthers SG,
- Feldman RD, Campbell N, Larochelle P, Bolli P, Burgess ED, Carruthers SG, et al. 1999 Canadian recommendations for the management of hypertension. Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension. CMAJ 1999;161(Suppl 12):S1-17.
- Canadian Pharmacists Association. Compendium of pharmaceuticals and specialties. 38th ed. Ottawa: The Association; 2003. p. 1044-7.
- Anderson RJ, Duchin KL, Gore RD, Herman TS, Michaels RS, Nichola PS, et al. Once-daily fosinopril in the treatment of hypertension. Hypertension 1991;17:636-42.

Correspondence to: Dr. W.E.S. Connolly, Chief of Ophthalmology, St. Mary's Hospital, 107–5165 Sherbrooke St. W, Montréal QC H4A 1T6; wesc@wesconnolly.com



Please, reader, can you spare some time?

Our annual *CMAJ* readership survey begins September 22. By telling us a little about who you are and what you think of *CMAJ*, you'll help us pave our way to an even better journal. For 2 weeks, we'll be asking you to take the survey route on one of your visits to the journal online. We hope you'll go along with the detour and help us stay on track.